araag2/HINT huggingface dataset:
Clinical trial NCT00991939 (phase 3, status: terminated)
Conditions: immune thrombocytopenic purpura
ICD codes: D69.3
Drugs: dexamethasone usp micronized, prednisone
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C
Reason stopped: 
    the study was closed due to accrual futility there were only a total of 8 subjects enrolled.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Must meet criteria for a diagnosis of ITP as specified by ASH guidelines

          -  Must be within 30 days after diagnosis of ITP at the time of randomization (diagnosis
             of ITP starts with first platelet count ≤ 100,000/μl)

          -  Platelet count ≤ 30,000/μl at the time ITP is diagnosed, and/or at some time between
             the diagnosis of ITP and study entry

          -  Platelet count ≤ 150,000/μl at the time of randomization

          -  Age ≥ 15 years

          -  If bone marrow examination is available, it must be compatible with ITP

          -  Subjects, or their legal guardians, must have the ability to provide informed consent

        Exclusion Criteria:

          -  Rituximab therapy or splenectomy for ITP or for any other cause within the previous 8
             weeks.

          -  Known HIV infection

          -  Known HCV infection

          -  Known systemic lupus erythematosus

          -  Pregnancy or breastfeeding

          -  Insulin-requiring diabetes mellitus

          -  Previous exposure to prednisone for ITP at a dose ≥ 1.5 mg/kg prednisone/day for ≥ 1
             week prior to study entry

          -  Ongoing use of treatments that are known to inhibit platelet function, e.g. aspirin

          -  Anything that in the opinion of the investigator is likely to interfere with
             participation in the study

          -  Persons previously randomized in the ITP^2 study

          -  Persons currently enrolled in other interventional clinical trials

          -  Exposure to thrombopoietic agent prior to study entry

          -  Previous exposure to dexamethasone for the treatment of ITP at a dose of 30 mg/day or
             greater for subjects < 60 kg or 40 mg/day or greater for subjects >= 60 kg for at
             least four days
Clinical trial NCT00600028 (phase 3, status: completed)
Conditions: idiopathic pulmonary fibrosis, cough
ICD codes: J84.112, R05.1, R05.2, R05.3, R05.4, R05.9, G44.83, J45.991
Drugs: thalidomide, placebo
SMILES: CC(C)NCC(O)COC1=CC=CC2=C1C=CC=C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic pulmonary fibrosis for >3 months <5 years

          -  High resolution CT scan of chest consistent with IPF within the previous 12 months

          -  FVC > 40% and < 90% predicted, TLC >40% <80%, DLCo >30% <90%

          -  Chronic Cough - cough >8 weeks

          -  Age >50

          -  Non-child bearing potential

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Women of child bearing potential

          -  Known etiology of lung fibrosis other than IPF

          -  Significant respiratory toxin exposure

          -  Collagen Vascular Disease

          -  Use of narcotic anti-cough agent in last week

          -  significant peripheral vascular disease or neuropathy

          -  history of seizures

          -  poorly controlled diabetes

          -  allergy to thalidomide
Clinical trial NCT01180400 (phase 3, status: completed)
Conditions: major depressive disorder, depression
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: tc-5214, placebo
SMILES: CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated informed consent before initiation of any study-related
             procedures.

          -  The patient must have a clinical diagnosis of major depressive disorder (MDD) with
             inadequate response to no more than one antidepressant.

          -  Out-patient status at enrollment and randomization.

        Exclusion Criteria:

          -  Patients with a lifetime history of bipolar disorder, psychotic disorder or
             post-traumatic stress disorder.

          -  Patients with a history of suicide attempts in the past year and/or seen by the
             investigator as having a significant history of risk of suicide or homicide.

          -  History of renal insufficiency or impairment or conditions that could affect
             absorption or metabolism of the investigational product in this patient population
Clinical trial NCT00449722 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: mesalazine
SMILES: NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria (main):

          -  Active ulcerative colitis except proctitis, i.e. inflammation minimal 15cm ab ano,
             confirmed by endoscopy and histology

          -  Established or new diagnosis

          -  Disease activity at baseline: Clinical Activity Index (CAI) >4 and Endoscopic Index
             (EI) >= 4

        Exclusion Criteria (main):

          -  Crohn's disease

          -  Toxic megacolon

          -  Present or past colorectal cancer

          -  Symptomatic gastrointestinal disease

          -  Serious secondary disease(s)

          -  Baseline stool positive for germs causing bowel disease

          -  Immunosuppressants within 3 months and/or corticosteroids within 1 month prior to
             baseline

          -  Current relapse occurred under maintenance treatment with >2g/day mesalazine

          -  Serum creatinine >= 1.2x upper limit of normal (ULN) and creatinine clearance < 60
             ml/min per 1.73 m2

          -  Serum transaminase (ALT and/or AST), and/or alkaline phosphatase >= 2x ULN
Clinical trial NCT00266032 (phase 3, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: flexible (extended) treatment of ee20/drsp (yaz, bay86-5300), fixed extended treatment of ee20/drsp (yaz, bay86-5300), standard 24+4 treatment of ee20/drsp (yaz, bay86-5300)
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy women who desire contraception

          -  smokers ≤ 30 Years old

        Exclusion Criteria:

          -  Contraindication against use of hormonal contraceptives
Clinical trial NCT02005562 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: mycophenolate mofetil, mycophenolate mofetil, anti-il-2r, methylprednisolone, cyclosporine
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, aged 18-75 years of age;

          -  in receipt of first donor kidney;

          -  eligible to receive immunosuppressive treatment comprising IRL2, CellCept,
             cyclosporine and steroids;

          -  eligible to receive oral treatment from the first day post-transplantation.

        Exclusion Criteria:

          -  patients receiving a second or subsequent kidney transplant, or multi-organ
             transplant;

          -  history of malignancy in the last 5 years (except successfully treated squamous cell
             or basal cell cancer and cervical cancer in situ);

          -  patients with active hepatitis B and/or hepatitis C, or HIV infection.
Clinical trial NCT00003216 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: fluorouracil, gemcitabine hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the pancreas

               -  Stage T1-4, N0-1 (stage I-IVA)

               -  No M1 or NX staging

               -  Primary tumor of the pancreas (pancreatic head, neck, uncinate process, or
                  body/tail) and maximum diameter/dimension and tumor status at surgical margin
                  known

          -  Prior potentially curative gross resection within 3-8 weeks before study

          -  No non-adenocarcinomas, adenosquamous carcinomas, islet cell carcinomas, cystadenomas,
             cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct
             carcinoma, or ampullary carcinoma

          -  No recurrent disease

          -  Post-resection CA-19-9 level required

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  Karnofsky 60-100%

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  SGOT no greater than 5 times ULN

        Renal:

          -  Creatinine no greater than 1.5 times ULN

        Other:

          -  No significant nausea or vomiting

          -  No prior malignancy within the past 5 years except nonmelanomatous skin cancer or
             carcinoma in situ of the cervix

          -  Able to maintain adequate nutrition (at least 1,500 calories/day)

               -  Feeding tube allowed

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy

        Surgery:

          -  See Disease Characteristics
Clinical trial NCT00141271 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: geodon (ziprasidone), geodon (ziprasidone), placebo
SMILES: ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have a primary diagnosis of Bipolar I Disorder, most recent episode
             depressed, with or without rapid cycling, without psychotic features, as defined in
             Diagnostic and Statistical Manual (of Mental Disorders) - Fourth Edition - Text
             Revision (DSM-IV-TR) (296.5X) and confirmed by a structured Mini International
             Neuropsychiatric Interview (MINI)

        Exclusion Criteria:

          -  Subjects with a DSM-IV TR diagnosis of schizophrenia (295.XX), schizoaffective
             disorder (295.70), schizophreniform disorder (295.40), delusional disorder (297.1), or
             psychotic disorder not otherwise specified (298.9).

          -  Subjects with other DSM-IV TR Axis I or Axis II disorder (in addition to Bipolar I
             disorder) are ineligible if the comorbid condition is clinically unstable, requires
             treatment, or has been a primary focus of treatment within the 6 month period prior to
             screening.
Clinical trial NCT01295814 (phase 3, status: completed)
Conditions: interstitial cystitis
ICD codes: N30.10, N30.11
Drugs: adalimumab
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females ≥18 and ≤ 65 years of age previously diagnosed with Interstitial
             Cystitis

          -  Currently have symptoms of urinary urgency, frequency or pain for more than 6 months

          -  Urinating at least 7 times a day or having some urgency or pain (measured on linear
             analog scales)

          -  Must be post-menopausal or surgically sterile or willing to use an adequate form of
             birth control

          -  Not pregnant or lactating

          -  Capable of voiding independently

          -  Willing to provide informed consent to participate

        Exclusion Criteria:

          -  Have symptoms that are presently relieved on other medications for interstitial
             cystitis

          -  Have absence of nocturia

          -  Have symptoms that are relieved by antimicrobials or antibiotics.

          -  Have a body mass index (BMI) of >39 kg/m2

          -  Have uncontrolled hypertension

          -  Have Type I or type 2 diabetes

          -  Have active Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) infection,
             or who are known carriers (Hepatitis B) at Screening

          -  Have a positive tuberculosis test at screening

          -  Have had a urinary tract infection for 6 weeks

          -  Have had bacterial cystitis in previous 3 months

          -  Have had previous exposure to Humira® (adalimumab)

          -  Have taken investigational medication within 30 days of screening

          -  Have any other condition/disease which, in the opinion of the investigator, could
             compromise subject safety or confound the interpretation of study results

          -  Are unable or unwilling to comply with protocol requirements
Clinical trial NCT01487174 (phase 3, status: terminated)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: kd019, erlotinib
SMILES: COC1=C(OC[C@H]2C[C@H]3CN(C)C[C@H]3C2)C=C2N=CN=C(NC3=CC=C(Cl)C(Cl)=C3F)C2=C1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    kadmon has made a business decision to terminate the study due to slow enrollment. note the
    decision to terminate the study was not related to safety issues
  
Eligibility criteria:

        For Eligibility subjects must have:

          -  failed one or two previous courses of therapy.

          -  have no active brain metastasis. Treated non-active brain metastasis are acceptable.

          -  cannot have received an Epidermal Growth Factor Receptors inhibitor (Tarceva
             [erlotinib] or Iressa [gefitinib]) in the past.

          -  has demonstrated progressive disease.
Clinical trial NCT00662818 (phase 3, status: completed)
Conditions: migraine disorders, heart disease, cerebrovascular accident, tia (transient ischemic attack), vascular diseases, peripheral vascular diseases
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419, I11.0, I11.9, I27.1, I51.9, I09.9, I27.9, I01.8, A52.05, I67.81, I67.89, I67.9, I67.841, I67.858, I67.848, Z86.73, I73.9, D57.03, D57.213, G46.8, I73.89, I73.9, I73.89
Drugs: telcagepant, acetaminophen/paracetamol, placebo to telcagepant, placebo to acetaminophen/paracetamol
SMILES: [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CC(=O)NC1=CC=C(O)C=C1, [H][C@]1(CC[C@@]([H])(N=C(O)N2CCC(CC2)N2C(O)=NC3=C2C=CC=N3)C(=O)N(CC(F)(F)F)C1)C1=C(F)C(F)=CC=C1, CC(=O)NC1=CC=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Stable coronary artery disease for 3 months or more

          -  18 years of age or older with a history of migraine with or without aura

          -  Must use acceptable contraception throughout the study

        Exclusion Criteria:

          -  Pregnant, breast-feeding, or planning to become pregnant during this study

          -  50 years of age or older when migraines began

          -  Other pain syndromes that might interfere with study assessments, uncontrolled
             psychiatric conditions, dementia, or significant neurological disorders (other than
             migraine)

          -  History of gastric, or small intestinal surgery, or has a disease that causes
             malabsorption
Clinical trial NCT00688519 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: u0267, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects at least 12 years old and in good general health.

          -  Mild to moderate plaque-type psoriasis

        Exclusion Criteria:

          -  Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs;
             or to any component of the investigational formulations

          -  History of hypercalcemia or of vitamin D toxicity.

          -  Diagnosis of generalized pustular or erythrodermic exfoliative psoriasis.

          -  Other serious skin disorder or any chronic medical condition that is not well
             controlled.

          -  Use of non-biologic systemic anti-psoriatic therapy or biologic therapy within four
             weeks of enrollment.

          -  Use of topical therapies that have a known beneficial effect on psoriasis, within 2
             weeks of enrollment.

          -  Systemic medications for other medical conditions that are known to affect psoriasis
             within the past four weeks of enrollment.

          -  Use of any investigational therapy within 4 weeks of enrollment.

          -  Pregnant women, women who are breast feeding, or sexually active women of child
             bearing potential who are not practicing an acceptable method of birth control.
Clinical trial NCT00506506 (phase 3, status: completed)
Conditions: chronic kidney disease
ICD codes: I12.9, N18.9, I12.0, D63.1, N18.1, N18.5, I13.0
Drugs: n-acetylcysteine, placebo
SMILES: CC(=O)N[C@@H](CS)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with an eGFR between 30-60 ml/min calculated using last available creatinine
             and patient weight.

          2. Age > 18

          3. No known allergies to or adverse effects from NAC

          4. No known scheduled radio-contrast procedures

          5. No medications known to affect creatinine secretion
Clinical trial NCT00424463 (phase 3, status: completed)
Conditions: amyotrophic lateral sclerosis (als)
ICD codes: G12.21
Drugs: mci-186, placebo of mci-186
SMILES: CC1=NN(C(=O)C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who ware completed drug administration without discontinuation in the
             preceding confirmatory study NCT00330681.

        Exclusion Criteria:

          -  Patients with such complications as Parkinson's disease, schizophrenia, dementia,
             renal failure, or other severe complication, and patients who have the anamnesis of
             hypersensitivity to edaravone.

          -  Patients whose creatinine clearance is 50mL/min or less at the time of completion of
             drug administration in the study NCT00330681.

          -  Pregnant, lactating, and probably pregnant patients, and patients who want to become
             pregnant, and patients who can not agree to contraception.

          -  Patients who are participating in other clinical trials except the study NCT00330681.

          -  In addition to the above exclusion criteria, patients judged to be inadequate to
             participate in this study by their physician.
Clinical trial NCT00400478 (phase 3, status: completed)
Conditions: diffuse large b-cell lymphoma (dlbcl), follicular nhl grade 3b
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  4 to 8 cycles R-CHOP/like, total of 8x Rituximab

          -  CR, CRu

          -  ECOG/ 0.1 or 2

          -  Known IPI at time of diagnosis

          -  Age > 18 years

          -  Negative pregnancy test

          -  Men must agree not to father a child during the therapy

        Exclusion Criteria:

          -  Transformed lymphoma

          -  Secondary malignancy

          -  Evidence of CNS - involvement

          -  Significant cardiac disease

          -  Creatinine > 2.0 mg/dl

          -  HIV, Hepatitis positive
Clinical trial NCT01182974 (phase 3, status: suspended)
Conditions: fever, sepsis
ICD codes: A78, A79.0, A93.1, A96.2, R50.82, R50.83, R50.9, A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7
Drugs: paracetamol, dypirone
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CN(CS(O)(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
Reason stopped: 
    difficulty in patient enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  age>18y

          -  hospitalized to int. med. dept. or ICU

          -  body temp>38 and one or more from the following:

               1. pulse>90 bpm

               2. resp. rate>20/min or PaCO2<32 mmHg

               3. WBC>12000 or <4000

          -  one of the following:

               1. hypotension

               2. disturbed end-organ perfusion (confusion, oliguria, lactic acidosis etc.)

        Exclusion Criteria:

          -  acute / chronic liver disease

          -  acute CNS disorder

          -  current isoniazid treatment

          -  alcoholism

          -  active malignancy

          -  pregnancy

          -  TPN or PPN
Clinical trial NCT00529087 (phase 3, status: completed)
Conditions: constipation
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: n-methylnaltrexone bromide (moa-728)
SMILES: C[N@+]1(CC2CC2)CC[C@]23[C@H]4OC5=C(O)C=CC(C[C@@H]1[C@]2(O)CCC4=O)=C35
Eligibility criteria:

        Inclusion Criteria:

          -  Adult outpatients with opioid-induced constipation and chronic non-malignant pain.

          -  Taking oral, transdermal, intravenous, or subcutaneous opioids.

          -  Willingness to discontinue all pre-study laxative therapy and use only study permitted
             rescue laxatives.

        Exclusion Criteria

          -  History of chronic constipation before the initiation of opioid therapy.

          -  Other GI disorders known to affect bowel transit.

          -  Women who are pregnant, breast-feeding, or plan to become pregnant.